The Lungs as a Portal of Entry for Systemic Drug Delivery
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The lung is naturally permeable to all small-molecule drugs studied and to many therapeutic peptides and proteins. Absorption can be estimated using a simple animal test, intratracheal instillation. Inhalation offers a noninvasive route for the delivery of peptides and proteins that otherwise must be injected. Peptides that have been chemically altered to inhibit peptidase enzymes exhibit very high bioavailabilities by the pulmonary route. Natural mammalian peptides, less than about 30 amino acids, are broken down in the lung by ubiquitous peptidases and have very poor bioavailabilities. In general, proteins with molecular weights between 6,000 and 50,000 D are relatively resistant to most peptidases and have good bioavailabilities following inhalation. For larger proteins the bioavailability picture is not clear. Although the lung is rich in antiproteases, aggregation of inhaled proteins will stimulate opsonization (coating) by special proteins in the lung lining fluids, which will then mark the aggregated proteins for phagocytosis and intracellular enzymatic destruction. Small peptides and proteins are absorbed more rapidly after inhalation than after subcutaneous injection. For other small molecules, inhalation is also a fast way to get into the body because drug efflux transporters and metabolizing enzymes are present in the lung at much lower levels than the gastrointestinal tract. Lipophilic small molecules are absorbed extremely fast, t1/2 (abs) approximately 1 to 2 minutes. Water-soluble small molecules are absorbed rapidly t1/2 (abs) approximately 65 minutes. Small molecules can exhibit prolonged absorption if they are highly insoluble or highly cationic. Encapsulation in slow release particles such as liposomes can also be used to control absorption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung biology in health and disease
Horsmanheimo, M., & Fudenberg, H. H. (1977) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(77)90040-x · Cited by 796
Mechanisms of macromolecule absorption by the lungs
Patton, J. S. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00113-l · Cited by 641
Self-citationHeyder, J. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-046ta · Cited by 601 · cited 1×
“In the last 20 years many advances have been made in the design of particles and devices to deliver therapeutic aerosols reliably, and with lung deposition efficiencies between 30 and 60% of what is loaded into the device (10, 11 ).”
BackgroundReceptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life
Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 402
Patton, J. S., Bukar, J., & Nagarajan, S. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00074-x · Cited by 193
Self-citationTronde, A., Nordén, B. O., Marchner, H., Wendel, A., Lennernäs, H., & Bengtsson, U. H. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10386 · Cited by 158
Absorption of saccharides and urea from the rat lung
Enna, S., & Schanker, L. S. (1972) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1972.222.2.409 · Cited by 139
Inhalation Delivery of Therapeutic Peptides and Proteins
Adjei, A. L., & Gupta, P. (1997) · doi:10.1201/9781420001242 · Cited by 136
Absorption of drugs from the rat lung
Enna, S., & Schanker, L. S. (1972) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1972.223.5.1227 · Cited by 128
Colthorpe, P., Farr, S. J., Taylor, G., Smith, L. J., & Wyatt, D. J. (1992) · Pharmaceutical Research · doi:10.1023/a:1015851521551 · Cited by 124
Cited by
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Inhaling medicines: delivering drugs to the body through the lungs
Patton, J. S., & Byron, P. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2153 · Cited by 1,331
Self-citationFrom Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 643
Chitosan-based delivery systems for protein therapeutics and antigens
Amidi, M., Mastrobattista, E., Jiskoot, W., & Hennink, W. E. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.009 · Cited by 620
Weber, S., Zimmer, A., & Pardeike, J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.08.013 · Cited by 568
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Corsonello, A., Pedone, C., & Incalzi, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416326 · Cited by 391
Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn059 · Cited by 345
Sakagami, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.012 · Cited by 331
“As a result, this route of administration has received significant attention as a noninvasive entry port to the systemic circulation, specifically for macromolecules, such as proteins and peptides that are otherwise effective only by injection [4–8].”
BackgroundDrug Delivery to the lungs: Challenges and Opportunities
Newman, S. P. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0037 · Cited by 328
Magnetically enhanced nucleic acid delivery. Ten years of magnetofection—Progress and prospects
Plank, C., Zelphati, O., & Mykhaylyk, O. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.08.002 · Cited by 316
Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes
Borghardt, J. M., Kloft, C., & Sharma, A. (2018) · Canadian Respiratory Journal · doi:10.1155/2018/2732017 · Cited by 304
Ruge, C. A., Kirch, J., & Lehr, C.-M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70072-9 · Cited by 280
Dry powder inhalation: past, present and future
de Boer, A. H., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F., & Frijlink, H. W. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1224846 · Cited by 271
Particle Transport and Deposition: Basic Physics of Particle Kinetics
Tsuda, A., Henry, F. S., & Butler, J. P. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c100085 · Cited by 264
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
“to have efficient and increased deposition in the lower airways, the aerodynamic size should be \3 lm [40].”
BackgroundPatil-Gadhe, A., Kyadarkunte, A., Patole, M., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.007 · Cited by 84
Thomas, C., Gupta, V., & Ahsan, F. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.006 · Cited by 79
Metadata
- Authors
- Patton, J. S., Fishburn, C. S., & Weers, J. G.
- Venue
- Proceedings of the American Thoracic Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12-01
- Volume
- 1
- Issue
- 4
- Pages
- 338-344
- ISSN
- 1546-3222 (ISSN-L)
- 1943-5665
- OpenAlex
- W2124596793
- Cited by
- 563
- References
- 38
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.